Z14UnD58_400x400.png
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 07:00 ET | InspireMD, Inc.
- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on...
Z14UnD58_400x400.png
InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
July 25, 2023 08:00 ET | InspireMD, Inc.
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention...
Z14UnD58_400x400.png
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
June 26, 2023 08:00 ET | InspireMD, Inc.
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform ...
Z14UnD58_400x400.png
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 18, 2023 08:00 ET | InspireMD, Inc.
TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
Z14UnD58_400x400.png
InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update
May 16, 2023 07:00 ET | InspireMD, Inc.
           - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over...
Z14UnD58_400x400.png
InspireMD Announces Private Placement of Up to $113.6 Million
May 15, 2023 08:00 ET | InspireMD, Inc.
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4...
Z14UnD58_400x400.png
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
May 12, 2023 16:05 ET | InspireMD, Inc.
- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent...
Z14UnD58_400x400.png
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
May 05, 2023 08:00 ET | InspireMD, Inc.
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent...
Z14UnD58_400x400.png
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
May 01, 2023 08:00 ET | InspireMD, Inc.
Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system ...
Z14UnD58_400x400.png
InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update
April 27, 2023 08:00 ET | InspireMD, Inc.
TEL AVIV, Israel, April 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...